NRIX Nurix Therapeutics
- 15.540
- +0.370+2.44%
- 15.790
- +0.250+1.61%
Nurix Therapeutics News
Express News | Nurix Therapeutics Appoints Paula G. O’connor, M.d., as Chief Medical Officer and Pasit Phiasivongsa, Ph.d., as Chief Technical Officer
Viking, CRISPR, Intellia Among Potential M&A Targets: Wells Fargo
Nurix Therapeutics Names New Board Chair
Nurix Therapeutics (NRIX) said late Monday that David Lacey has stepped down as board chair following the conclusion of its annual stockholders' meeting. Lacey will remain on the board and will contin
Nurix Therapeutics Says David Lacey Steps Down From Chair Role And Will Remain Board Member And Retain Committee Leadership Roles; Current Board Member Julia Gregory Elected New Board Chair
Nurix Therapeutics Says David Lacey Steps Down From Chair Role And Will Remain Board Member And Retain Committee Leadership Roles; Current Board Member Julia Gregory Elected New Board Chair
Press Release: Nurix Therapeutics Announces Board Chair Transition
Nurix Therapeutics Announces Board Chair Transition David L. Lacey steps down from chair role and will remain board member and retain committee leadership roles Current board member Julia P. Gregory
Nurix Therapeutics (NRIX) Moves 7.7% Higher: Will This Strength Last?
Nurix Therapeutics Gains Buy Rating Amid Strong Clinical Advances for CLL Drug NX-5948
Stifel: Maintains Nurix Therapeutics (NRIX.US) rating, adjusted from buy to buy rating, target price $27.00.
Stifel: Maintains Nurix Therapeutics (NRIX.US) rating, adjusted from buy to buy rating, target price $27.00.
Stifel Maintains Buy on Nurix Therapeutics, Maintains $27 Price Target
Stifel analyst Stephen Willey maintains Nurix Therapeutics with a Buy and maintains $27 price target.
Stifel Nicolaus Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)
Needham Reiterates Buy on Nurix Therapeutics, Maintains $31 Price Target
Needham analyst Gil Blum reiterates Nurix Therapeutics (NASDAQ:NRIX) with a Buy and maintains $31 price target.
Analysts Are Bullish on Top Healthcare Stocks: Unicycive Therapeutics (UNCY), Nurix Therapeutics (NRIX)
Nurix Therapeutics Announces Upcoming Oral Presentation of New Data From Ongoing Clinical Trial of NX-5948, a Selective Bruton's Tyrosine Kinase (BTK) Degrader, at the European Hematology Association Congress (EHA2024)
Overall response rate of 70% observed in 10 evaluable heavily pretreated CLL patients Data showcase deepening clinical responses with longer time on therapy in CLL patients including patients with resistance mutations
Nurix Therapeutics Initiated at Overweight by Stephens & Co.
Nurix Therapeutics Initiated at Overweight by Stephens & Co.
Nurix Therapeutics (NRIX.US) was first covered by Stephens & Co. with an incremental rating, with a target price of $20.00.
Nurix Therapeutics (NRIX.US) was first covered by Stephens & Co. with an incremental rating, with a target price of $20.00.
Stephens & Co. Initiates Coverage On Nurix Therapeutics With Overweight Rating, Announces Price Target of $20
Stephens & Co. analyst Sudan Loganathan initiates coverage on Nurix Therapeutics with a Overweight rating and announces Price Target of $20.
Nurix Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 42.76% Stephens & Co. → $20 Initiates Coverage On → Overweight 04/11/2024 64.17% RBC Capital $2
Nurix Therapeutics to Participate in RBC Capital Markets Global Healthcare Conference
SAN FRANCISCO, May 07, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat pat
Nurix Therapeutics(NRIX.US) Officer Sells US$44,878.17 in Common Stock
$Nurix Therapeutics(NRIX.US)$ Officer van Houte Hans sold 3,499 shares of common stock on May 2, 2024 at an average price of $12.826 for a total value of $44,878.17.Source: Announcement What is statem
Analysts' Top Healthcare Picks: Evolent Health (EVH), Nurix Therapeutics (NRIX)
Analysis
Price Target
No Data
